243 related articles for article (PubMed ID: 32209253)
1. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
Okuno T; Arakawa S; Yoshida T; Ohe Y
Lung Cancer; 2020 May; 143():95-96. PubMed ID: 32209253
[No Abstract] [Full Text] [Related]
2. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis.
Yoshida H; Ooi M; Kim YH
J Thorac Oncol; 2018 Nov; 13(11):e219-e220. PubMed ID: 30368410
[No Abstract] [Full Text] [Related]
5. Detection of Meningeal Metastasis in the Cerebrospinal Fluid in Lung Adenocarcinoma: Case Report.
Zhang YJ; Li H; Zhong R; Chen W; Kou G; Liu G; Cheng Y
Clin Lung Cancer; 2020 Sep; 21(5):e493-e496. PubMed ID: 32418825
[No Abstract] [Full Text] [Related]
6. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
Yang JCH; Kim SW; Kim DW; Lee JS; Cho BC; Ahn JS; Lee DH; Kim TM; Goldman JW; Natale RB; Brown AP; Collins B; Chmielecki J; Vishwanathan K; Mendoza-Naranjo A; Ahn MJ
J Clin Oncol; 2020 Feb; 38(6):538-547. PubMed ID: 31809241
[TBL] [Abstract][Full Text] [Related]
7. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Liu J; Jin B; Su H; Qu X; Liu Y
BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
[TBL] [Abstract][Full Text] [Related]
8. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
9. Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid.
Théoleyre S; Masson I; Herbreteau G; Vallée A; Sénellart H; Denis MG
Lung Cancer; 2017 Dec; 114():111-112. PubMed ID: 29096978
[No Abstract] [Full Text] [Related]
10. Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring EGFR20 R776S, C797S, and EGFR21 L858R compound EGFR mutations: a case report.
Jia G; Bashir S; Ye M; Li Y; Lai M; Cai L; Xu M
Anticancer Drugs; 2024 Jul; 35(6):542-547. PubMed ID: 38513197
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
Wang M; Zhu F; Luo N; Li M; Qi Y; Wang M
Medicine (Baltimore); 2021 Nov; 100(44):e27727. PubMed ID: 34871271
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib 160 mg daily for advanced non-small cell lung cancer with leptomeningeal metastasis: A case report.
Tsang MW
Asia Pac J Clin Oncol; 2019 Oct; 15 Suppl 6():5-7. PubMed ID: 31642175
[TBL] [Abstract][Full Text] [Related]
13. Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.
Yan Y; Jiang G; Ma W; Li T; Wang L
Clin Lung Cancer; 2020 Nov; 21(6):562-567. PubMed ID: 32622727
[No Abstract] [Full Text] [Related]
14. Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations.
Ikari T; Sakakibara-Konishi J; Yamamoto G; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N
Clin Lung Cancer; 2019 Jul; 20(4):e531-e533. PubMed ID: 31164318
[No Abstract] [Full Text] [Related]
15. Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication.
Hirokawa E; Watanabe S; Sakai K; Takeda M; Sato C; Takahama T; Nishio K; Nakagawa K
Thorac Cancer; 2021 Aug; 12(16):2283-2287. PubMed ID: 34240806
[TBL] [Abstract][Full Text] [Related]
16. Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed.
Zheng S; Li H; Feng J; Jiang C; Lin Y; Xie Y; Yu T; Qian X; Yin Z
Anticancer Drugs; 2022 Jan; 33(1):e795-e798. PubMed ID: 34486539
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib in the treatment of leptomeningeal disease in T790M-negative, epidermal growth factor receptor-mutated non-small cell lung cancer: a case report.
Chen J; Soudy H
Chin Clin Oncol; 2019 Jun; 8(3):29. PubMed ID: 30943730
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Cho JH; Lim SH; An HJ; Kim KH; Park KU; Kang EJ; Choi YH; Ahn MS; Lee MH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Clin Oncol; 2020 Feb; 38(5):488-495. PubMed ID: 31825714
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
[TBL] [Abstract][Full Text] [Related]
20. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
